Evidence map›Paper›PMID 30320148›Full record

ArticleOpen forum infectious diseases2018

Results of Early Virologic Monitoring May Facilitate Differentiated Care Monitoring Strategies for Clients on ART, Rakai, Uganda.

Victor Ssempijja, Larry W Chang, Gertrude Nakigozi, Anthony Ndyanabo, Thomas C Quinn, Frank Cobelens, Maria Wawer, Ronald Gray, David Serwadda, Steven J Reynolds

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Victor SsempijjaClinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., NCI Campus at Frederick, Frederick, Maryland.ORCID 0000-0003-2609-6525
Larry W ChangRakai Health Sciences Program, Kalisizo, Uganda.
Gertrude NakigoziRakai Health Sciences Program, Kalisizo, Uganda.
Anthony NdyanaboRakai Health Sciences Program, Kalisizo, Uganda.
Thomas C QuinnJohns Hopkins School of Medicine, Baltimore, Maryland.
Frank CobelensDepartment of Global Health and Amsterdam Institute for Global Health and Development, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Maria WawerRakai Health Sciences Program, Kalisizo, Uganda.
Ronald GrayRakai Health Sciences Program, Kalisizo, Uganda.
David SerwaddaRakai Health Sciences Program, Kalisizo, Uganda.
Steven J ReynoldsRakai Health Sciences Program, Kalisizo, Uganda.

Funding

International Center for Excellence in Research (ICER) in Uganda: Impact of ARVsZIAAI001040 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REYNOLDS, STEVEN · 2009 to 2025
$23.5M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
International Center for Excellence in Research (ICER) in Uganda: Impact of ARVsZ01AI001040 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI QUINN, THOMAS · 2008 to 2008
$2.2M
Multidisciplinary Research Training to Understand and Reduce HIV Incidence in UgandaD43TW010557 · FIC · JOHNS HOPKINS UNIVERSITY · PI CHANG, LARRY WILLIAM · 2018 to 2022
$1.6M
CCR NIH HHS HHSN261200800001CFIC NIH HHS D43 TW010557Intramural NIH HHS Z01 AI001040NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

backgroundViral load (VL) monitoring is standard of care in HIV-infected persons initiated on antiretroviral therapy (ART). We evaluated the predictive value of VL measurements at 6 and 12 months after initiation of firstline ART to estimate the future risk of virologic failure (VF).

methodsHIV-infected persons with VL measurements at 6 and 12 months post-ART initiation and at least 2 additional VL measurements thereafter were assessed for risk of future VF, defined per World Health Organization guidelines. VL at 6 or 12 months post-ART was categorized into <400, 400-1000, 1001-2000, and >2000 copies/mL. Cox proportional hazard models were used to compare VF incidence associated with 6-month, 12-month, and a composite of 6- and 12-month VL prediction indicators.

resultsOverall, 1863 HIV-infected adults had a 6- and 12-month VL measurement, and 1588 had at least 2 additional VLs thereafter for predicting future VF. The majority (67%) were female (median age: females 33 years and males 37 years). At 12 months post-ART, 90% had VL<400 copies/mL (cumulative incidence of VF at 1.5%), 3% had 400-1000 copies/mL (VF 12%), 2% had 1001-2000 copies/mL (VF 22%), and 5% had >2000 copies/mL (VF 71%). The predictive value of the 12-month VL measurement was comparable to the composite of both the 6- and 12-month VL measurements and better than the 6-month VL measurement.

conclusionsAt 12 months after ART initiation, 90% of patients were virally suppressed with a low likelihood of future VF. VL measurement at 12 months post-ART initiation predicts risk of VF and could inform differentiated virologic monitoring strategies.

Indexed as

antiretroviral therapydifferentiated careHIV/AIDSviral load monitoringviral suppression

Identifiers

PMID30320148
PMCPMC6176337

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.